No Evidence of Pritelivir Resistance Among Herpes Simplex Virus Type 2 Isolates After 4 Weeks of Dai...
No Evidence of Pritelivir Resistance Among Herpes Simplex Virus Type 2 Isolates After 4 Weeks of Daily Therapy
About this item
Full title
Author / Creator
Publisher
United States: Oxford University Press
Journal title
Language
English
Formats
Publication information
Publisher
United States: Oxford University Press
Subjects
More information
Scope and Contents
Contents
Background, Pritelivir is a novel helicase-primase inhibitor in clinical development for treatment of herpes simplex virus type 2 (HSV-2) infections. In preclinical work, resistance-mediating mutations were identified in the HSV-2 genome at 3 loci in the UL5 gene and 1 locus in UL52. Methods. To evaluate whether daily pritelivir treatment results i...
Alternative Titles
Full title
No Evidence of Pritelivir Resistance Among Herpes Simplex Virus Type 2 Isolates After 4 Weeks of Daily Therapy
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4918824
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4918824
Other Identifiers
ISSN
0022-1899
E-ISSN
1537-6613
DOI
10.1093/infdis/jiw129
